Literature DB >> 22498198

Medulloblastoma: progress over time.

Robert I Smee1, Janet R Williams, Katie J De-Loyde, Nicola S Meagher, Richard Cohn.   

Abstract

INTRODUCTION: Medulloblastoma is the most common central nervous system tumour in children aged 0-4 years, with 75% of cases occurring in patients <16 years, and rare in adults. The intent of this audit is to review a single centre's experience and to compare outcomes with other centres' outcomes.
METHODS: This Ethics approved retrospective audit evaluates the paediatric population aged <16 years who received radiotherapy as their initial or salvage treatment at the Prince of Wales Hospital Cancer Centre between 1972 and 2007. The primary and secondary end-points were progression-free survival (PFS) and cancer-specific survival (CSS), with comparisons made between patients treated before and after 1990, and the impact of high- and low-risk disease.
RESULTS: There were 80 eligible patients, 78 who had radiotherapy at initial presentation, and 2 at the time of recurrence. Median age was 6.5 years, 52 were boys and 28 were girls. Seventy-eight patients had a surgical procedure and ultimately received craniospinal radiotherapy. Of these 78 patients, 32 (40%) had a macroscopically complete resection. The 5-year PFS was 69.7%. The 5-year PFS for patients treated pre and post 1990 was 66.1% and 71.8%, respectively. The 5-year CSS for high- and low-risk patients was 61.1% and 78.4%, respectively. Ultimately, 33% of patients were dead due to disease.
CONCLUSION: This audit demonstrates those children referred to this facility for treatment have comparable survival to that of other major centres.
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Year:  2012        PMID: 22498198     DOI: 10.1111/j.1754-9485.2012.02349.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy.

Authors:  Anand Maurya; Upendra Kumar Patel; Jitendra Kumar Yadav; Virender Pratap Singh; Alka Agarwal
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Stem cell therapies for the treatment of radiation-induced normal tissue side effects.

Authors:  Marc Benderitter; Fabio Caviggioli; Alain Chapel; Robert P Coppes; Chandan Guha; Marco Klinger; Olivier Malard; Fiona Stewart; Radia Tamarat; Peter van Luijk; Charles L Limoli
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

3.  Neuroprotection of Radiosensitive Juvenile Mice by Ultra-High Dose Rate FLASH Irradiation.

Authors:  Yasaman Alaghband; Samantha N Cheeks; Barrett D Allen; Pierre Montay-Gruel; Ngoc-Lien Doan; Benoit Petit; Patrik Goncalves Jorge; Erich Giedzinski; Munjal M Acharya; Marie-Catherine Vozenin; Charles L Limoli
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

4.  NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma.

Authors:  Eleni Frisira; Fatima Rashid; Swastina Nath Varma; Sara Badodi; Valentine Ayodele Benjamin-Ombo; David Michod; Maria Victoria Niklison-Chirou
Journal:  Cell Death Dis       Date:  2019-10-16       Impact factor: 8.469

5.  Oxamate, but Not Selective Targeting of LDH-A, Inhibits Medulloblastoma Cell Glycolysis, Growth and Motility.

Authors:  Cara J Valvona; Helen L Fillmore
Journal:  Brain Sci       Date:  2018-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.